peptide-therapy
The FDA Is Shutting Down One Peptide Market and Opening Another
Most coverage treats peptide regulation as one story. The reality is bifurcated: GLP-1 copycat compounding is being crushed, while 14 other peptides are being reviewed for restored legal access.